Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging
Open Access
- 1 January 2011
- journal article
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 7 (2) , 60-68
Abstract
Shim YS, et al. J Clin Neurol. 2011 Jun;7(2):60-68. https://doi.org/10.3988/jcn.2011.7.2.60Keywords
This publication has 79 references indexed in Scilit:
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer DiseaseArchives of Neurology, 2009
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Longitudinal Study of the Transition From Healthy Aging to Alzheimer DiseaseArchives of Neurology, 2009
- Biomarkers of Alzheimer's diseaseNeurobiology of Disease, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991